Carcinoembryonic antigen (CEA) is an antigen that is overexpressed in colorectal cancers and is considered a suitable target for its treatment. Uppsala University discussed research in the development of the lutetium-177-radiolabeled anti-CEA hT84.66-M5A monoclonal antibody (MAb) 177Lu-DOTA-M5A for the treatment of colorectal cancers and its combination studies with the HSP90 inhibitor onalespib.
At the recent EANM meeting, Point Biopharma Global Inc. presented preclinical details on the development of 177Lu-PNT2001 and 225Ac-PNT2001 for the treatment of prostate cancer.
Investigators have developed α-therapeutic thorium-227-labeled DUNP19 ([227Th]Th-DUNP19), an antibody-conjugated radiopharmaceutical with high specificity and affinity to LRRC15.
Bolt Biotherapeutics Inc. has presented new 2-amino-4-carboxamide-benzazepine antibody-drug conjugates (ADCs) comprising antibodies covalently linked to TLR7 and/or TLR8 agonists through a linker and reported to be useful for the treatment of cancer.
Domain Therapeutics SA has received clinical trial application (CTA) clearances in France and Belgium for its immuno-oncology program DT-9081, allowing the initiation of a phase I trial for solid tumors.
Sumitomo Pharma Oncology Inc. has patented (furopyrimidin-4-yl)piperazine compounds acting as DNA repair protein RAD51 homolog 1 (RAD51) expression inhibitors reported to be useful for the treatment of cancer.
RSS
